title: Results of primary central nervous system lymphoma treated by radiation and chemotherapy: retrospective analysis of twelve institutions in the Tokai District of Japan, 1995-1999.
abstract: OBJECTIVE
  We analyzed the therapeutic results and prognostic factors of 46 primary central nervous system lymphoma (PCNSL) patients who were treated at twelve institutions in the Tokai district of Japan between 1995 and 1999. We compared the results with those of a Japanese nationwide survey performed in the past.
  
  
  METHODS
  We sent each institution a questionnaire about the state of patients' disease, pathological type, method and doses of radiotherapy, regimen and intensity of chemotherapy, and patients' prognoses. The range of patients' ages was 33 to 93 years (median, 61 years). Thirty-one were men and 15 were women. The most prevalent histology was diffuse large B cell type (33 patients). We used the Kaplan-Meier method to calculate the survival rate and Cox's proportional hazards model to analyze the prognostic factors.
  
  
  RESULTS
  The five-year cumulative survival rate was 25%, and the median survival time was 22.7 months. The five-year disease-free survival rate was 23%. In monovariate analysis, patients who were both younger than 60 years old and had a WHO performance status (PS) score equal to or less than 2 showed a better survival rate. Furthermore, the patients receiving systemic chemotherapy showed a significantly better local control rate. In addition, patients who received systemic chemotherapy achieved a higher complete remission rate than those not receiving it. However, no factors that significantly influenced survival rate were identified in multivariate analysis.
  
  
  CONCLUSIONS
  We demonstrated that the therapeutic outcome of PCNSL patients has recently improved. In particular, patients with good PS showed better local control than those with poor PS. However, we could not identify any significant prognostic factors in PCNSL patients.
authors.affiliation: Department of Radiology, Aichi Medical University, Japan.
authors.forename: Toshiki
authors.initials: T
authors.lastname: Kawamura
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Ishiguchi
authors.forename: Yuta
authors.initials: Y
authors.lastname: Shibamoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ogino
authors.forename: Shunichi
authors.initials: S
authors.lastname: Ishihara
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Yamada
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Katada
authors.forename: Kazunori
authors.initials: K
authors.lastname: Suzuki
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Suzuki
authors.forename: Mikio
authors.initials: M
authors.lastname: Mimura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007564:Japan; D008223:Lymphoma / Q000188:drug therapy* / Q000532:radiotherapy*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D015996:Survival Rate; D016896:Treatment Outcome